Business Description
Pyxis Oncology Inc
NAICS : 325412
SIC : 2834
ISIN : US7473241013
Description
Pyxis Oncology Inc is a preclinical oncology company focused on developing an arsenal of next-generation therapeutics to target difficult-to-treat cancers and improve quality of life for patients. It develops the product candidates with the objective to directly kill tumor cells, and to address the underlying pathologies created by cancer that enable its uncontrollable proliferation and immune evasion.
Financial Strength
7/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 5.59 | |||||
| Equity-to-Asset | 0.72 | |||||
| Debt-to-Equity | 0.17 | |||||
| Debt-to-EBITDA | -0.27 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EBITDA Growth Rate | -53 | |||||
| 3-Year EPS without NRI Growth Rate | -47.2 | |||||
| 3-Year FCF Growth Rate | -54.8 |
Momentum Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 33.16 | |||||
| 9-Day RSI | 38.79 | |||||
| 14-Day RSI | 42.43 | |||||
| 6-1 Month Momentum % | 145.51 | |||||
| 12-1 Month Momentum % | 37.28 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 4.84 | |||||
| Quick Ratio | 4.84 | |||||
| Cash Ratio | 4.63 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -26.5 | |||||
| Shareholder Yield % | -1.69 |
Profitability Rank
1/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -51.11 | |||||
| ROA % | -39.68 | |||||
| ROIC % | -201.5 | |||||
| ROC (Joel Greenblatt) % | -322.51 | |||||
| ROCE % | -49.92 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.61 | |||||
| Price-to-Tangible-Book | 1.99 | |||||
| EV-to-EBIT | -1.84 | |||||
| EV-to-Forward-EBIT | -0.13 | |||||
| EV-to-EBITDA | -1.89 | |||||
| EV-to-Forward-EBITDA | -0.14 | |||||
| EV-to-Forward-Revenue | 152.01 | |||||
| EV-to-FCF | -1.96 | |||||
| Price-to-Net-Current-Asset-Value | 2.64 | |||||
| Price-to-Net-Cash | 2.84 | |||||
| Earnings Yield (Greenblatt) % | -54.35 | |||||
| FCF Yield % | -29.5 |
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers